We have located links that may give you full text access.
Differential expression of urocortin in human testicular germ cells in course of spermatogenesis: role for urocortin in male fertility?
Urology 2009 April
OBJECTIVES: To provide the first insights into the potential role of urocortin in mammalian spermatogenesis, we studied the expression of urocortin and corticotropin-releasing factor receptors 1 and 2 in the human testis. Urocortin is a bioactive peptide with antiapoptotic and antiproliferative properties. The proper regulation of apoptosis and proliferation is of high physiologic relevance in the control of spermatogenesis in adulthood and of the noncycling stage of gonocytes in fetal life.
METHODS: Using polymerase chain reaction analysis and immunohistochemistry, the expression and tissue localization of urocortin on mRNA and at the peptide level was studied in 9 normal adult, 5 fetal, and 5 Sertoli cell-only testicular specimens. Tissue localization of corticotropin-releasing factor receptors in normal adults was considered using immunohistochemistry.
RESULTS: We found that urocortin mRNA was present in all adult specimens tested and that the urocortin peptide was expressed in elongating spermatids, mature spermatozoa, and peritubular myoid cells, and to a lesser extent in Leydig cells. Corticotropin-releasing factor receptor 1 was mainly expressed in spermatogonia, spermatocytes, and Leydig cells, and corticotropin-releasing factor receptor 2 was mostly expressed in spermatogonia. The antibodies against urocortin produced a nuclear staining in fetal gonocytes. No significant immunopositivity for urocortin could be observed in the Sertoli cell-only specimens.
CONCLUSIONS: The expression of urocortin in normal adult and fetal testicular germ cells in the cell division arrest phases suggests a probable role for this peptide in the pathophysiology of germ cell differentiation and division. In human germ cells, the separate location of urocortin and its receptors indicates a receptor-independent action of urocortin in the course of spermatogenesis.
METHODS: Using polymerase chain reaction analysis and immunohistochemistry, the expression and tissue localization of urocortin on mRNA and at the peptide level was studied in 9 normal adult, 5 fetal, and 5 Sertoli cell-only testicular specimens. Tissue localization of corticotropin-releasing factor receptors in normal adults was considered using immunohistochemistry.
RESULTS: We found that urocortin mRNA was present in all adult specimens tested and that the urocortin peptide was expressed in elongating spermatids, mature spermatozoa, and peritubular myoid cells, and to a lesser extent in Leydig cells. Corticotropin-releasing factor receptor 1 was mainly expressed in spermatogonia, spermatocytes, and Leydig cells, and corticotropin-releasing factor receptor 2 was mostly expressed in spermatogonia. The antibodies against urocortin produced a nuclear staining in fetal gonocytes. No significant immunopositivity for urocortin could be observed in the Sertoli cell-only specimens.
CONCLUSIONS: The expression of urocortin in normal adult and fetal testicular germ cells in the cell division arrest phases suggests a probable role for this peptide in the pathophysiology of germ cell differentiation and division. In human germ cells, the separate location of urocortin and its receptors indicates a receptor-independent action of urocortin in the course of spermatogenesis.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app